Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Δ